



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Feb 10th, 2015

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Sreet, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice Presdient (Legal & Corp Affairs)



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref:PR/17/2015

Press Release

**NATCO announces USFDA Filings for Fingolimod, 0.5mg Capsules and
Cabazitaxel 60mg/1.5ml Injection**

Hyderabad, India, February 10th, 2015

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it has filed Abbreviated New Drug Applications (ANDAs) for Fingolimod, 0.5mg Capsules & Cabazitaxel, 60mg/1.5ml Injection, with the U.S. Federal Drug Administration (USFDA), through its respective marketing partners in the USA.

Natco & its associated marketing partners for the above products in the USA, believe that they are the first company to have filed a substantially complete ANDA which includes a paragraph IV certification for **Fingolimod, 0.5mg Capsules & Cabazitaxel, 60mg/1.5ml Injection**, providing 180 days of marketing exclusivity upon its final USFDA approval.

Novartis sells Fingolimod 0.5mg Capsules under Brand name Gilenya®, in the USA market and used for the treatment of certain patients with multiple sclerosis. The market size of Gilenya® in the USA is approximately US\$1.2 Billion for twelve months ending September 2014, according to IMS Health.

Sanofi sells Cabazitaxel 60mg/1.5ml Injection under Brand name Jevtana®, in the USA market and used for the treatment of certain patients with hormone-refractory prostate cancer. The market size of Jevtana® in the USA is approximately US\$116.8 Million for twelve months ending September 2014, according to IMS Health.

All trademarks are the property of their respective owners.

Forwarded for favour of publication
For NATCO Pharma Limited

M Adinarayana

**M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)**